Adagene (Group)

https://www.adagene.com

Adagene (Suzhou, China and San Francisco, California) is a clinical stage biotech company with innovative antibody discovery and engineering technologies. By utilizing its proprietary Dynamic Precision Library Platform (DPL) and SAFEbody technologies, Adagene is showcasing its exceptional antibody engineering capabilities building franchises of second and third-generation antibody products. Adagene’s lead program, ADG106, is a CD-137 agonist currently in phase I in US and China. Adagene is backed by top tier global venture funds including F-Prime Capital Partners, Eight Roads Ventures, Wuxi Pharmatech Healthcare Fund I L.P., GP Healthcare Capital, New World TMT Ltd and Sequoia China. The company has raised over $85 million through its series A to C financing. *

	Start	2011-01-01 established
	Industry	antibody technology
	Industry 2	therapeutic antibody
	Person	Luo, Peizhi (Peter) (Adagene 201904 CEO + Founder before Abmaxis)
	Person 2	Tam, Raymond (Adagene 201202 CFO)

	Region	Suzhou
	Country	China
	Street	Xinghu Street Suzhou Industrial Park, 4F, Bldg. C14, No. 218
	City	n. a. Suzhou
	Tel	+86-512-87773632
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2020-12-31)
	Currency	USD
	Annual sales	480,000 (licensing revenue (2019) 2019-12-31)
	Profit	-16,432,308 (2019-12-31)
	Cash	92,532,788

		* Document for »About Section«: ADC Therapeutics S.A.. (4/24/19). "Press Release: ADC Therapeutics and Adagene Announce License Agreement". Lausanne & Suzhou.

		Record changed: 2023-07-10